ABSTRACT
BACKGROUND Alpha globin is expressed in the endothelial cells of human resistance arteries where it binds to endothelial nitric oxide synthase and limits release of the vasodilator nitric oxide. Genomic deletion of the alpha globin gene (HBA) is common among Black Americans and could lead to increased endothelial nitric oxide signaling and reduced risk of hypertension.
METHODS Community-dwelling US adults aged 45 years or older were enrolled and examined from 2003 to 2007, followed by telephone every 6 months, and reexamined from 2013 to 2016. At both visits, trained personnel performed standardized, in-home blood pressure measurements and pill bottle review. Prevalent hypertension was defined as systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90mmHg or anti-hypertensive medication use. Droplet digital PCR was used to determine HBA copy number. The associations of HBA copy number with prevalent hypertension, resistant hypertension, and incident hypertension were estimated using multivariable regression.
RESULTS Among 9,684 Black participants, 7,439 (77%) had hypertension at baseline and 1,044 of those had treatment-resistant hypertension. 1,000 participants were not hypertensive at baseline and participated in a follow up visit; 517 (52%) developed hypertension over median 9.2 years follow-up. Increased HBA copy number was not associated with prevalent hypertension (PR=1.00; 95%CI 0.98,1.02), resistant hypertension (PR=0.95; 95%CI 0.86,1.05), or incident hypertension (RR=0.96; 95%CI 0.86,1.07).
CONCLUSIONS There were no associations between increased HBA copy number and risk of hypertension. These findings suggest that variation in alpha globin gene copy number does not modify the risk of hypertension among Black American adults.
Competing Interest Statement
Dr. Gutierrez discloses receiving grant funding and consulting fees from Akebia Therapeutics; grant funding and consulting fees from Amgen; grant funding from GlaxoSmithKline; and consulting fees Reata, AstraZeneca, and Ardelyx; and serving on the Data Monitoring Committee for QED Therapeutics.
Funding Statement
This is an ancillary study supported by cooperative agreement U01 NS041588 co-funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Service. This research was supported in part by the Divisions of Intramural Research, National Institute of Allergy and Infectious Diseases project AI001150 (A.P.R., H.C.A), National Heart, Lung, and Blood Institute (NHLBI) project HL006196 (A.P.R., Y.Y., H.C.A.). This work was also funded in part by the National Cancer Institute (NCI) Intramural Research Program under contract HHSN26120080001E (C.A.W), and the NHLBI grants K08HL12510 (R.P.N.) and K08HL096841 (N.A.Z.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS, NIA, NIAID, NCI, or NHLBI. The content of this publication does not necessarily reflect the view or policy of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the government. The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the U.S. government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants provided oral and written informed consent. The Institutional Review Board of the University of Alabama at Birmingham, the lead study center, approved this study. In addition, the REGARDS study was approved by participating center Institutional Review Boards. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Minor revisions
Data Availability
The data underlying the findings include potentially identifying participant information and cannot be made publicly available because of ethical/legal restrictions. However, data including statistical code from this article are available to researchers who meet the criteria for access to confidential data. Data can be obtained upon request through the University of Alabama at Birmingham at regardsadmin{at}uab.edu. Additional information on the REGARDS study is available at www.regardsstudy.org.
